Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone

• Published in: PloS one Vol. 17; no. 9; p. e0273854
• Main Authors: Májek, Ondrej, Gregor, Jakub, Mogulkoc, Nesrin, Lewandowska, Katarzyna, Sterclová, Martina, Müller, Veronika, Hájková, Marta, Kramer, Mordechai R, Tekavec-Trkanjec, Jasna, Jovanovic, Dragana, Studnicka, Michael, Stoeva, Natalia, Kirchgässler, Klaus-Uwe, Littnerová, Simona, Dusek, Ladislav, Vasáková, Martina Koziar
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 01.09.2022; Public Library of Science (PLoS)
• Subjects: Biology and Life Sciences; Biopsy; Care and treatment; Diagnosis; Dyspnea; Fibrosis; Histopathology; Lung diseases; Lung transplants; Lungs; Medical diagnosis; Medical prognosis; Medicine and Health Sciences; Patients; Pulmonary fibrosis; Research and Analysis Methods; Respiratory function; Statistical analysis; Survival; Czech Republic
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0273854

Background There is no clear evidence whether pirfenidone has a benefit in patients with probable or possible UIP, i.e. when idiopathic pulmonary fibrosis (IPF) is diagnosed with a lower degree of diagnostic certainty. We report on outcomes of treatment with pirfenidone in IPF patients diagnosed with various degrees of certainty. Methods and findings We followed patients in the multi-national European MultiPartner IPF Registry (EMPIRE) first seen between 2015 and 2018. Patients were assessed with HRCT, histopathology and received a multi-disciplinary team (MDT) IPF diagnosis. Endpoints of interest were overall survival (OS), progression-free survival (PFS) and lung function decline. Results A total of 1626 patients were analysed, treated with either pirfenidone (N = 808) or receiving no antifibrotic treatment (N = 818). When patients treated with pirfenidone were compared to patients not receiving antifibrotic treatment, OS (one-, two- and three-year probability of survival 0.871 vs 0.798; 0.728 vs 0.632; 0.579 vs 0.556, P = 0.002), and PFS (one-, two- and three-year probability of survival 0.597 vs 0.536; 0.309 vs 0.281; 0.158 vs 0.148, P = 0.043) was higher, and FVC decline smaller (-0.073 l/yr vs -0.169 l/yr, P = 0.017). The benefit of pirfenidone on OS and PFS was also seen in patients with probable or possible IPF. Conclusions This EMPIRE analysis confirms the favourable outcomes observed for pirfenidone treatment in patients with definitive IPF and indicates benefits also for patients with probable or possible IPF.